Tests drugs to prevent graft-versus-host disease after transplant in young blood cancer patients
Tests drugs to prevent graft-versus-host disease after transplant in young blood cancer patients.
Plain-language title generated from the registry record
Registry title: Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Key facts
- Where
- Moscow, RussiaSee the site
- Phase
- Phase 2/3
Where in Russia
- National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy RogachyovMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Trial code
- NCT06756152
- Record updated
- 1 January 2025
- Original description
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donorsRead full original descriptionShow less
Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide with Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis After Hematopoietic Stem Cell Transplantation from an Unrelated or Haploidentic Donor
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Inclusion: Patients under the age of 21 years with following diseases:; acute lymphoblastic,; myeloblastic,; biphenotypic,; bilinear leukemia,; malignant lymphoma,; myelodysplastic syndrome,.
Exclusion: Uncontrolled viral, fungal or bacterial infection; Mental illness of the patient or caregivers, making it impossible to realize the essence of the study and compromising compliance with medical appointments and sanitary and hygienic regime 1 These patients may receive treatment according to the protocol, but the results will be evaluated separately; Clinical status:; Lansky/Karnowski index <70% (supplement No.1); Heart function: left ventricular ejection fraction <40% according to ultrasound of the heart1; Kidney function: clearance of endogenous creatinine < 70 ml / min; Liver function: total bilirubin, ALT, AST, ALP > 2 norms; Lung function: lung capacity <50%, for children who cannot carry out of respiratory function - oxygen saturation during pulse oximetry <92%; Age over 21 years; Patients with ALL outside clinical and hematological remission.